DZ2936A1 - Composition nouvelle à libération modifiée pour letraitement du diabète. - Google Patents

Composition nouvelle à libération modifiée pour letraitement du diabète.

Info

Publication number
DZ2936A1
DZ2936A1 DZ990236A DZ990236A DZ2936A1 DZ 2936 A1 DZ2936 A1 DZ 2936A1 DZ 990236 A DZ990236 A DZ 990236A DZ 990236 A DZ990236 A DZ 990236A DZ 2936 A1 DZ2936 A1 DZ 2936A1
Authority
DZ
Algeria
Prior art keywords
diabetes
treatment
modified release
release composition
new modified
Prior art date
Application number
DZ990236A
Other languages
English (en)
Inventor
Karen Dr Lewis
Donald Dr Mackenzie
Vincenzo Colin-Re
Nicola Jayne Lilliott
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2936(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9824867.7A external-priority patent/GB9824867D0/en
Priority claimed from GBGB9824866.9A external-priority patent/GB9824866D0/en
Priority claimed from GBGB9824869.3A external-priority patent/GB9824869D0/en
Priority claimed from GBGB9912193.1A external-priority patent/GB9912193D0/en
Priority claimed from GBGB9912191.5A external-priority patent/GB9912191D0/en
Priority claimed from GBGB9912190.7A external-priority patent/GB9912190D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2936A1 publication Critical patent/DZ2936A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
DZ990236A 1998-11-12 1999-11-10 Composition nouvelle à libération modifiée pour letraitement du diabète. DZ2936A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9824867.7A GB9824867D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9824866.9A GB9824866D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9824869.3A GB9824869D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912193.1A GB9912193D0 (en) 1999-05-25 1999-05-25 Novel composition and use
GBGB9912191.5A GB9912191D0 (en) 1999-05-25 1999-05-25 Novel composition and use
GBGB9912190.7A GB9912190D0 (en) 1999-05-25 1999-05-25 Novel composition and use

Publications (1)

Publication Number Publication Date
DZ2936A1 true DZ2936A1 (fr) 2004-03-15

Family

ID=27547326

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990236A DZ2936A1 (fr) 1998-11-12 1999-11-10 Composition nouvelle à libération modifiée pour letraitement du diabète.

Country Status (36)

Country Link
EP (3) EP1992337A1 (fr)
JP (1) JP2002529504A (fr)
KR (1) KR100643833B1 (fr)
CN (1) CN1230162C (fr)
AR (1) AR024228A1 (fr)
AT (1) ATE406889T1 (fr)
AU (1) AU768994B2 (fr)
BG (2) BG109852A (fr)
BR (1) BR9915285A (fr)
CA (1) CA2351058A1 (fr)
CY (1) CY1108587T1 (fr)
CZ (1) CZ20011629A3 (fr)
DE (1) DE69939485D1 (fr)
DK (1) DK1131070T3 (fr)
DZ (1) DZ2936A1 (fr)
EA (2) EA007610B1 (fr)
ES (1) ES2312221T3 (fr)
HK (1) HK1040910B (fr)
HR (1) HRP20010343B1 (fr)
HU (1) HUP0104303A3 (fr)
ID (1) ID28783A (fr)
IL (2) IL143002A0 (fr)
MY (1) MY124695A (fr)
NO (1) NO20012303L (fr)
NZ (1) NZ511614A (fr)
OA (1) OA11677A (fr)
PE (1) PE20001238A1 (fr)
PL (1) PL347634A1 (fr)
PT (1) PT1131070E (fr)
SI (1) SI1131070T1 (fr)
SK (1) SK287038B6 (fr)
TR (1) TR200101333T2 (fr)
TW (2) TW592694B (fr)
UY (1) UY25799A1 (fr)
WO (1) WO2000028989A1 (fr)
YU (1) YU37301A (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
AU777776B2 (en) 1999-12-23 2004-10-28 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
AU2007201729B2 (en) * 1999-12-23 2010-02-25 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
US8257744B2 (en) * 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
CA2427195C (fr) * 2000-11-03 2009-10-06 Andrx Corporation Compositions de metformine a liberation controlee
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
CA2434169C (fr) 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Systeme de liberation espacee de medicaments
WO2002074285A1 (fr) * 2001-03-16 2002-09-26 Andrx Corporation Preparation de sulfonyluree a liberation controlee
FR2822069B1 (fr) * 2001-03-19 2003-06-20 Lipha Composition pharmaceutique comprenant un compose stimulant la secretion d'insuline et un derive de thiazolidinedione et son utilisation pour la preparation de medicamments destines a traiter le diabete
JP2004534056A (ja) * 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
AU2001273290B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. Core formulation comprising troglitazone and a biguanide
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
US7183321B2 (en) 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
EP1474108A2 (fr) 2002-01-09 2004-11-10 Enzrel, Inc. Administration medicamenteuse par liposomes de composes anti-inflammatoires, antioxydants, aromatiques ou polycycliques
PE20030800A1 (es) * 2002-02-12 2003-10-31 Glaxo Group Ltd Forma de dosificacion oral de liberacion controlada
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
PL376577A1 (pl) * 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
CA2514879C (fr) 2003-01-03 2014-09-16 Shire Laboratories Inc. Utilisation d'un melange de deux ou de plusieurs matieres d'enrobage enteriques afin de reguler la liberation de medicaments
AU2004208606B2 (en) 2003-01-29 2009-09-24 Takeda Pharmaceutical Company Limited Process for producing coated preparation
UY28457A1 (es) * 2003-08-07 2005-03-31 Sb Pharmco Inc Nueva composición
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
GB0320522D0 (en) * 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
RU2359661C2 (ru) 2003-10-31 2009-06-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
JP2007534704A (ja) * 2004-04-29 2007-11-29 美時化学製薬股▲ふん▼有限公司 経口徐放性錠剤組成物およびその製造方法
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
KR100657785B1 (ko) * 2005-02-19 2007-04-16 한국유나이티드제약 주식회사 글리메피리드, 메트포르민 및 은행엽엑스를 함유하는 약학적 조성물
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
MXPA05010977A (es) * 2005-10-12 2007-04-11 Abdala Leopoldo Espinosa Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus.
MXPA05014092A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
NZ569071A (en) 2005-12-22 2011-01-28 Takeda Pharmaceutical Solid preparation containing an insulin sensitizer
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
WO2008073282A2 (fr) * 2006-12-07 2008-06-19 Schering Corporation Formulation de matrice sensible au ph
ES2350029T3 (es) * 2007-03-02 2011-01-17 Farnam Companies, Inc. Pellets de liberación sostenida que comprenden un material tipo cera.
TW200906383A (en) * 2007-08-02 2009-02-16 Handok Pharmaceuticals Co Ltd Sustained-release formulation comprising metformin acid salt
DK2200606T3 (en) 2007-09-10 2017-12-04 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF RELATIONSHIP USED AS INHIBITORS OF SGLT
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
CN101548961B (zh) * 2008-04-03 2011-05-04 单宝华 一种治疗糖尿病及肥胖症的口服胶囊制剂
WO2010026467A2 (fr) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Forme pharmaceutique à libération prolongée de principe actif hautement soluble
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
ME02634B (fr) 2009-10-14 2017-06-20 Janssen Pharmaceutica Nv Procédé de préparation de composés utiles comme inhibiteurs de sglt2
TWI599360B (zh) 2010-05-11 2017-09-21 健生藥品公司 醫藥調配物
AU2011276332A1 (en) * 2010-07-06 2013-01-17 Janssen Pharmaceutica Nv Formulation for co-therapy treatment of diabetes
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
LT2661266T (lt) * 2011-01-07 2020-12-10 Anji Pharma (Us) Llc Gydimo būdai chemosensorinio receptoriaus ligando pagrindu
ME02469B (fr) 2011-04-13 2017-02-20 Janssen Pharmaceutica Nv Procédé de préparation de composés utiles en tant qu'inhibiteurs de sglt2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
EP2800561B1 (fr) * 2012-01-06 2020-08-19 Anji Pharma (US) LLC Compositions à base de biguanide et procédés de traitement de troubles métaboliques
MX2014008189A (es) 2012-01-06 2015-02-12 Elcelyx Therapeutics Inc Composiciones y metodos para tratar trastornos metabolicos.
CN102631332A (zh) * 2012-04-28 2012-08-15 邹立兴 一种伏格列波糖片剂及其制备方法
KR101409330B1 (ko) * 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
WO2014128116A1 (fr) * 2013-02-19 2014-08-28 Sanovel Ilac Sanayi Ve Ticaret A.S. Procédé de production de formulations de gliclazide
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
US4538469A (en) * 1983-07-29 1985-09-03 Panametrics, Inc. Integrated threshold arming method and apparatus
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1989008650A1 (fr) 1988-03-08 1989-09-21 Pfizer Inc. Agents hypoglycemiques de thiazolidinedione
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
WO1991007107A1 (fr) 1989-11-13 1991-05-30 Pfizer Inc. Agents d'oxazolidinedione hypoglycemiques
JP2630016B2 (ja) * 1990-05-21 1997-07-16 ヤマハ株式会社 吹奏感付加器を有する電子管楽器
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
HUT65619A (en) 1990-07-03 1994-07-28 Yamanouchi Pharma Co Ltd Process for producing bisheterocyclic compounds and pharmaceutical preparations containing them
WO1992003425A1 (fr) 1990-08-23 1992-03-05 Pfizer Inc. Derives d'hydroxy-uree hypoglycemique
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
HUT68370A (en) 1991-04-11 1995-06-28 Takeda Chemical Industries Ltd Thiazolidine derivatives, pharmaceutical compositions containing them and process for their production
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (fr) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
JPH07505647A (ja) 1992-04-10 1995-06-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 複素環化合物および２型糖尿病の治療におけるそれらの使用
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
DE69331010D1 (de) 1992-07-03 2001-11-29 Smithkline Beecham Plc Benzoxazol- und benzothiazol-derivate als arzneimittel
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
RU2071783C1 (ru) * 1993-09-07 1997-01-20 Ессентукский центральный военный санаторий Способ получения средства для лечения сахарного диабета
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
RU2114617C1 (ru) * 1996-09-27 1998-07-10 Юрий Георгиевич Каминский Антидиабетическое средство на основе янтарной кислоты
NZ337927A (en) * 1997-03-24 2000-11-24 Galderma Res & Dev Methods and compositions for treating and/or preventing non-insulin dependent diabetes mellitus (NIDDM) using specific retinoid compounds
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment

Also Published As

Publication number Publication date
EP1992337A1 (fr) 2008-11-19
JP2002529504A (ja) 2002-09-10
SK287038B6 (sk) 2009-10-07
DK1131070T3 (da) 2008-11-17
NO20012303D0 (no) 2001-05-10
TR200101333T2 (tr) 2001-10-22
HRP20010343B1 (en) 2010-11-30
KR20010080419A (ko) 2001-08-22
BG65351B1 (bg) 2008-03-31
YU37301A (sh) 2005-06-10
NZ511614A (en) 2003-12-19
AU768994B2 (en) 2004-01-15
OA11677A (en) 2005-01-12
HUP0104303A2 (hu) 2002-03-28
ES2312221T3 (es) 2009-02-16
EP1813273A1 (fr) 2007-08-01
TW200418453A (en) 2004-10-01
HK1040910A1 (en) 2002-06-28
EA011633B1 (ru) 2009-04-28
CA2351058A1 (fr) 2000-05-25
EA200601145A1 (ru) 2009-04-28
EA007610B1 (ru) 2006-12-29
SI1131070T1 (sl) 2008-12-31
CN1348369A (zh) 2002-05-08
EP1131070B1 (fr) 2008-09-03
CZ20011629A3 (cs) 2001-12-12
CY1108587T1 (el) 2014-04-09
BG105568A (en) 2002-01-31
SK6442001A3 (en) 2001-12-03
UY25799A1 (es) 2000-12-29
PL347634A1 (en) 2002-04-22
WO2000028989A1 (fr) 2000-05-25
HK1040910B (zh) 2009-06-26
IL143002A (en) 2007-02-11
AU3033800A (en) 2000-06-05
NO20012303L (no) 2001-07-04
BR9915285A (pt) 2001-08-07
TWI251487B (en) 2006-03-21
KR100643833B1 (ko) 2006-11-10
ID28783A (id) 2001-07-05
BG109852A (bg) 2008-11-28
PE20001238A1 (es) 2001-01-11
TW592694B (en) 2004-06-21
DE69939485D1 (de) 2008-10-16
ATE406889T1 (de) 2008-09-15
EP1131070A1 (fr) 2001-09-12
EA200100541A1 (ru) 2001-10-22
HUP0104303A3 (en) 2003-12-29
HRP20010343A2 (en) 2002-06-30
MY124695A (en) 2006-06-30
PT1131070E (pt) 2008-11-19
IL143002A0 (en) 2002-04-21
CN1230162C (zh) 2005-12-07
AR024228A1 (es) 2002-09-25

Similar Documents

Publication Publication Date Title
DZ2936A1 (fr) Composition nouvelle à libération modifiée pour letraitement du diabète.
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
DK1112106T3 (da) Serotonerge 5HT2-agonister til behandling af glaukom
NO993646D0 (no) Tiazol benzensulfonamider som <beta>3-agonister for behandling av diabetes og fedme
DE69917957D1 (de) Blockcopolymerzusammensetzung für die Modifikation von Asphalt, und Asphaltzusammensetzung enthaltend diese Blockcopolymerzusammensetzung
MA26822A1 (fr) Composes pour le traitement d'une ischemie.
NO964548D0 (no) Substituerte sulfonamider som selektive 3 agonister for behandling av diabetes og fedme
HUP0103856A2 (hu) Gyógyszerkészítmény akut rendellenességek kezelésére
TR199501229A2 (tr) Yeni bilesim.
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
DK1206436T3 (da) Retinoider til behandling af emfysem
DZ3155A1 (fr) Nouvelle composition pharmaceutique.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
DE69908845D1 (de) Fotoresistzusammensetzung
FR2718351B1 (fr) Procédé pour la déformation permanente des matières kératiniques.
BR9907304B1 (pt) refratÁrio de alumina-magnÉsia-grafita.
FR2844453B1 (fr) Utilisation de pre-biotiques pour la prevention de l'installation du diabete de type ii
DK199800837A (da) Anlæg til behandling af emner
NO20012727L (no) 3,4,5-trisubstituerte arylnitronforbindelser og farmasöytiske sammensetninger som inneholder samme
TR199903132A3 (tr) Metalosan bilesiklerinin aktive edici kompozisyonu.
DE69800451T2 (de) Antiferroelektrische Flüssigkristallzusammensetzung
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
PT1069885E (pt) Solucao oftalmica que compreende glicogenio
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
TR199902015A3 (tr) Aril-sikloheksilamin türevlerinin CNS bozukluklarina karsi kullanilmasi.